ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.641,30
0,25%
S&P 500
5.477,90
0,16%
US Dollar vs BRL
5,5238
0,00%
Bitcoin
61.038,82
0,37%
Brent Oil
84,265
-0,24%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. MEI Pharma Inc (MEIP)

  7. MEI Pharma Inc (MEIP) Notícias

MEIP

MEI Pharma (MEIP)

MEI Pharma Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MEIP
DataHoraFonteTítuloCódigoCompanhia
21/05/202417:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MEIPMEI Pharma Inc
21/05/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
09/05/202417:02Business WireMEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational HighlightsNASDAQ:MEIPMEI Pharma Inc
09/05/202417:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MEIPMEI Pharma Inc
11/04/202409:02Business WireMEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344NASDAQ:MEIPMEI Pharma Inc
11/04/202409:00Business WireMEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer PatientsNASDAQ:MEIPMEI Pharma Inc
10/04/202409:00Business WireMEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology ForumNASDAQ:MEIPMEI Pharma Inc
26/03/202409:00Business WireMEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid LeukemiaNASDAQ:MEIPMEI Pharma Inc
29/02/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MEIPMEI Pharma Inc
20/02/202419:33Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:MEIPMEI Pharma Inc
13/02/202419:05Business WireMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsNASDAQ:MEIPMEI Pharma Inc
16/01/202419:00Business WireMEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024NASDAQ:MEIPMEI Pharma Inc
12/01/202418:00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:MEIPMEI Pharma Inc
11/12/202314:00Business WireMEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023NASDAQ:MEIPMEI Pharma Inc
14/11/202322:59Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MEIPMEI Pharma Inc
09/11/202318:05Business WireMEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational HighlightsNASDAQ:MEIPMEI Pharma Inc
08/11/202319:04Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:MEIPMEI Pharma Inc
08/11/202319:03Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MEIPMEI Pharma Inc
08/11/202319:02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MEIPMEI Pharma Inc
08/11/202310:00Business WireMEI Pharma to Present at the Stifel 2023 Healthcare ConferenceNASDAQ:MEIPMEI Pharma Inc
06/11/202318:57Business WireMEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common StockNASDAQ:MEIPMEI Pharma Inc
02/11/202310:00Business WireMEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023NASDAQ:MEIPMEI Pharma Inc
01/11/202318:20Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MEIPMEI Pharma Inc
01/11/202318:15Edgar (US Regulatory)Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialNASDAQ:MEIPMEI Pharma Inc
01/11/202310:00Business WireMEI Pharma Enters into Agreement with Anson Funds and Cable Car CapitalNASDAQ:MEIPMEI Pharma Inc
27/10/202317:05Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:MEIPMEI Pharma Inc
17/10/202318:33Business WireMEI Pharma Recommends Stockholders Not to ConsentNASDAQ:MEIPMEI Pharma Inc
17/10/202318:28Edgar (US Regulatory)Form DEFC14A - Definitive proxy statement, contested solicitationsNASDAQ:MEIPMEI Pharma Inc
12/10/202318:25Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:MEIPMEI Pharma Inc
03/10/202307:33Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:MEIPMEI Pharma Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:MEIP

Seu Histórico Recente

TG
A3LHZR
BMW Finance
BTHB
ENJKRW
Enjin Coin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados